HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Physicians will remain in the loop, but AI can “turbocharge and augment our abilities,” an emergency medicine physician says.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

Mamas Mamas, Ruben de Winter, and Paul Knaapen discuss the results of the PROCTOR trial, which explored native vessel versus ...